InsidersTradesSigma
Track the AntriaBio, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 11 January 2016 (Cession). Among the most active insiders: Elam Nevan C. Every trade is openly available.
Analysts rate AntriaBio, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
AntriaBio, Inc. is a biopharmaceutical company focused on developing treatments for diabetes and other metabolic diseases. It is listed on NASDAQ under the ticker ABIO.